Within this scheme, cholesterol efflux is a first and rate-limiting step, and a residual RCT efficiency of 73–79% in CAD compared to control may be reasonably assumed based on APOA1 and ABCA1 expression changes (Figure 1). The gene discussed is APOA1; the disease is coronary artery disorder.